Submitted for Publication: September 13, 2010; final revision received January 24, 2011; accepted February 22, 2011.
Financial Disclosure: Dr Von Korff is principal investigator of work funded by a grant from Johnson& Johnson Inc to Group Health Research Institute. Dr Kessler has consulted for GlaxoSmithKline Inc, Kaiser Permanente, Pfizer Inc, sanofi-aventis, Shire Pharmaceuticals, and Wyeth-Ayerst; has served on advisory boards for Eli Lilly and Company and Wyeth-Ayerst; and has had research support for his epidemiologic studies from Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson& Johnson Pharmaceuticals, Ortho-McNeil Pharmaceuticals Inc, Pfizer Inc, and sanofi-aventis.
Funding/Support: The World Health Organization World Mental Health Surveys initiative is supported by grant R01 MH070884 from the National Institute of Mental Health; contract HHSN271200700030C from the Mental Health Burden Study; the John D. and Catherine T. MacArthur Foundation; the Pfizer Foundation; grants R13-MH066849, R01-MH069864, and R01 DA016558 from the US Public Health Service; grant R03-TW006481 from the Fogarty International Center; the Pan American Health Organization; Eli Lilly and Company; Ortho-McNeil Pharmaceutical; GlaxoSmithKline; and Bristol-Myers Squibb. The Colombian National Study of Mental Health is supported by the Ministry of Social Protection, with supplemental support from the Saldarriaga Concha Foundation. The European surveys were funded by contracts QLG5-1999-01042 and SANCO 2004123 from the European Commission; the Piedmont Region, Italy; grant FIS 00/0028 from the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain; grant SAF 2000-158-CE from the Ministerio de Ciencia y Tecnología, Spain; Departament de Salut, Generalitat de Catalunya, Spain; grants CIBER CB06/02/0046 and RETICS RD06/0011 REM-TAP from the Instituto de Salud Carlos III; and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. The World Mental Health Japan Survey is supported by the Research on Psychiatric and Neurological Diseases and Mental Health grants H13-SHOGAI-023, H14-TOKUBETSU-026, and H16-KOKORO-013 from the Japan Ministry of Health, Labour, and Welfare. The Mexican National Comorbidity Survey is supported by grant INPRFMDIES 4280 from the National Institute of Psychiatry Ramon de la Fuente and by grant CONACyT-G30544-H from the National Council on Science and Technology, with supplemental support from the PanAmerican Health Organization. The US National Comorbidity Survey Replication is supported by grant U01-MH60220 from the National Institute of Mental Health, with supplemental support from the National Institute of Drug Abuse, the Substance Abuse and Mental Health Services Administration, grant 044708 from the Robert Wood Johnson Foundation, and the John W. Alden Trust. A complete list of all within-country and cross-national WMH publications can be found at http://www.hcp.med.harvard.edu/wmh/.
Role of the Sponsors: The funders had no input into the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Disclaimer: The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of the sponsoring organizations, agencies, or governments.
Additional Contributions: We thank the staff of the World Mental Health Data Collection and Data Analysis Coordination Centers for assistance with instrumentation, fieldwork, and consultation regarding data analysis.